Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Sallée, Marion ^a   Ismail, Khalil ^a   Fakhouri, Fadi ^b   Vacher Coponat, Henri ^a   Moussi Francés, Julie ^a   Frémaux Bacchi, Véronique ^c   Burtey, Stéphane ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Complement; Hemolytic and uremic syndrome; Thrombocytopenia

Indexed keywords

CREATININE; HAPTOGLOBIN; HEMOGLOBIN; LACTATE DEHYDROGENASE;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; MALE; PREVALENCE; PROTEINURIA; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; COHORT STUDIES; COMORBIDITY; DIAGNOSIS, DIFFERENTIAL; FEMALE; FRANCE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 84871942008     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-3     Document Type: Article

References (17)

1. The pathogenesis and treatment of hemolytic uremic syndrome. Kaplan BS, Meyers KE, Schulman SL, J Am Soc Nephrol 1998 9 6 1126 1133 9621299
2. Antibodies to von willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. Tsai HM, Lian EC, N Engl J Med 1998 339 22 1585 1594 10.1056/NEJM199811263392203 9828246 (Pubitemid 28536133)
3. von willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, et al. N Engl J Med 1998 339 22 1578 1584 10.1056/NEJM199811263392202 9828245 (Pubitemid 28536132)
4. Atypical hemolytic-uremic syndrome related to abnormalities within the complement system. Fremeaux-Bacchi V, Fakhouri F, Roumenina L, Dragon-Durey MA, Loirat C, Rev Med Interne 2011 32 4 232 240 10.1016/j.revmed.2009.09.039 21376430
5. Atypical hemolytic-uremic syndrome. Noris M, Remuzzi G, N Engl J Med 2009 361 17 1676 1687 10.1056/NEJMra0902814 19846853
6. The interactive factor H-atypical hemolytic uremic syndrome mutation database and website, update and integration of membrane cofactor protein and factor I mutations with structural models. Saunders RE, Abarrategui-Garrido C, Fremeaux-Bacchi V, Goicoechea de Jorge E, Goodship TH, Lopez Trascasa M, Noris M, Ponce Castro IM, Remuzzi G, Rodriguez de Cordoba S, et al. Hum Mutat 2007 28 3 222 234 10.1002/humu.20435 17089378
7. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. Fremeaux-Bacchi V, Moulton EA, Kavanagh D, Dragon-Durey MA, Blouin J, Caudy A, Arzouk N, Cleper R, Francois M, Guest G, et al. J Am Soc Nephrol 2006 17 7 2017 2025 10.1681/ASN.2005101051 16762990 (Pubitemid 44036186)
8. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Goicoechea De Jorge E, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA, Garrido CA, Lopez-Trascasa M, Sanchez-Corral P, Morgan BP, Rodriguez De Cordoba S, Proc Natl Acad Sci U S A 2007 104 1 240 245 10.1073/pnas.0603420103 17182750 (Pubitemid 46068016)
9. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. Kavanagh D, Kemp EJ, Mayland E, Winney RJ, Duffield JS, Warwick G, Richards A, Ward R, Goodship JA, Goodship TH, J Am Soc Nephrol 2005 16 7 2150 2155 10.1681/ASN.2005010103 15917334 (Pubitemid 41716447)
10. Does complement factor B have a role in the pathogenesis of atypical HUS? Kavanagh D, Kemp EJ, Richards A, Burgess RM, Mayland E, Goodship JA, Goodship TH, Mol Immunol 2006 43 7 856 859 10.1016/j.molimm.2005.06.041 16061287 (Pubitemid 41814403)
11. Athrombocytopenic thrombotic microangiopathy, a condition that could be overlooked based on current diagnostic criteria. De Serres SA, Isenring P, Nephrol Dial Transplant 2009 24 3 1048 1050 19096082
12. Specific von willebrand factor-cleaving protease in thrombotic microangiopathies, a study of 111 cases. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP, Blood 2001 98 6 1765 1772 10.1182/blood.V98.6.1765 11535510
13. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschenes G, Gie S, et al. J Am Soc Nephrol 2007 18 8 2392 2400 10.1681/ASN.2006080811 17599974 (Pubitemid 47203855)
14. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. Fakhouri F, Roumenina L, Provot F, Sallee M, Caillard S, Couzi L, Essig M, Ribes D, Dragon-Durey MA, Bridoux F, et al. J Am Soc Nephrol 2010 21 5 859 867 10.1681/ASN.2009070706 20203157
15. Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count. Dorresteijn EM, van de Kar NC, Cransberg K, Pediatric nephrology 2012 27 7 1193 1195 10.1007/s00467-012-2130-z 22399074
16. Lessons learned from the oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome registry. George JN, Terrell DR, Swisher KK, Vesely SK, J Clin Apher 2008 23 4 129 137 10.1002/jca.20169 18618590
17. ADAMTS13 Activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake MA, Raskob GE, Blood 2003 102 1 60 68 10.1182/blood-2003- 01-0193 12637323 (Pubitemid 36759636)